OPEN ACCESS Freely available online

Journal of Pancreatic Disorders & Therapy

ISSN: 2165-7092

Short Communication

Epigenetic and Genetic Pathways Underlying Chemotherapy Failure in Pancreatic Cancer

Rowan Ashford*

Department of Oncology, Crestview University, Alderport City, United States

DESCRIPTION

Pancreatic cancer continues to present one of the most difficult challenges in oncology due to its aggressive nature and poor response to conventional therapies. Among the factors contributing to the limited efficacy of treatment, chemoresistance is a major barrier. Resistance to chemotherapy agents such as gemcitabine and fluorouracil reduces therapeutic options, accelerates disease progression, and contributes to low overall survival rates. Understanding the molecular mechanisms driving chemoresistance and exploring strategies to counteract it are essential for improving patient outcomes [1].

The development of chemoresistance in pancreatic cancer is multifactorial. Tumor heterogeneity allows subpopulations of cells to survive therapeutic pressure, with some clones inherently resistant due to genetic or epigenetic alterations. Mutations in key genes involved in DNA repair, apoptosis, and cell cycle regulation, including *TP53*, *KRAS*, and *SMAD4*, confer survival advantages under chemotherapeutic stress. These alterations can reduce drug-induced apoptosis, allowing malignant cells to persist despite treatment [2].

Alterations in drug transport and metabolism are also central to chemoresistance. Reduced drug uptake due to downregulation of nucleoside transporters, such as *hENT1*, limits intracellular accumulation of agents like gemcitabine. Concurrently, increased expression of efflux pumps, including members of the ATP-binding cassette family, actively removes chemotherapeutic compounds from cancer cells, decreasing their cytotoxicity. Additionally, metabolic enzymes that inactivate drugs can further diminish effectiveness [3].

The tumor microenvironment plays a pivotal role in mediating resistance. Dense desmoplastic stroma, characteristic of pancreatic cancer, creates physical barriers to drug delivery, reducing penetration into tumor tissue. Stromal cells, fibroblasts, and immune populations release cytokines and growth factors that activate survival pathways in cancer cells, including *PI3K/AKT, NF-κB*, and *MAPK* signaling. Hypoxia within poorly vascularized tumors induces adaptive responses that promote chemoresistance, such as the upregulation of drug-detoxifying enzymes and survival proteins [4].

Epigenetic changes contribute further complexity. DNA methylation, histone modifications, and non-coding RNA activity can modulate the expression of genes involved in drug sensitivity. For instance, microRNAs can suppress pro-apoptotic genes or enhance the expression of efflux transporters, reducing the effectiveness of chemotherapy. These epigenetic mechanisms are reversible, presenting potential targets for therapeutic intervention [5].

Strategies to overcome chemoresistance in pancreatic cancer are diverse and increasingly focused on precision approaches. Combination therapies that simultaneously target multiple resistance pathways have demonstrated promise in preclinical models. For example, pairing cytotoxic agents with inhibitors of survival signaling pathways can sensitize resistant tumor cells to treatment. Nanoparticle-based drug delivery systems are being explored to enhance tumor penetration and increase local drug concentration, bypassing stromal barriers [6].

Targeting the tumor microenvironment represents another therapeutic avenue. Agents that disrupt stromal density or inhibit stromal signaling can improve drug delivery and restore chemosensitivity. Immune modulation, through checkpoint inhibitors or cytokine-targeted therapies, may also enhance the effectiveness of chemotherapy by promoting antitumor immunity and reducing protective stromal effects [7].

Biomarker-driven approaches are critical to identify patients at risk of chemoresistance and to guide treatment selection. Expression levels of transporters, enzymes, and signaling molecules can inform responsiveness to specific agents. Molecular profiling of tumors allows stratification of patients and personalization of therapeutic regimens, potentially improving outcomes and avoiding ineffective treatments [8].

Emerging therapies targeting epigenetic regulators, autophagy pathways, and metabolic adaptations are under investigation. By inhibiting mechanisms that enable cancer cells to survive chemotherapeutic stress, these approaches aim to restore sensitivity to conventional agents. Clinical trials evaluating

Correspondence to: Rowan Ashford, Department of Oncology, Crestview University, Alderport City, United States, E-mail: isabella.thorne@medresearchmail.org

Received: 22-Sep-2025, Manuscript No. PDT-26-40566; **Editor assigned:** 24-Sep-2025, PreQC No. PDT-26-40566 (PQ); **Reviewed:** 08-Oct-2025, QC No. PDT-26-40566; Revised: 15-Oct-2025, Manuscript No. PDT-26-40566 (R); **Published:** 22-Oct-2025, DOI: 10.35248/2165-7092.25.15.390

Citation: Ashford R (2025). Epigenetic and Genetic Pathways Underlying Chemotherapy Failure in Pancreatic Cancer. Pancreat Disord Ther. 15:390.

combination regimens, novel inhibitors, and precision-guided therapies are ongoing, highlighting the evolving landscape of pancreatic cancer management [9,10].

CONCLUSION

Chemoresistance in pancreatic cancer arises from complex interactions among genetic alterations, cellular adaptations, stromal influences, and epigenetic modifications. Effective management requires a comprehensive understanding of these mechanisms and the implementation of strategies that enhance drug efficacy, overcome survival pathways, and exploit tumor vulnerabilities. Continued research, innovative therapeutic approaches, and integration of molecular diagnostics are essential to improve treatment outcomes and extend survival for patients facing this aggressive malignancy.

REFERENCES

1. Lankisch PG, Schreiber A, Otto J. Pancreolauryl test: evaluation of a tubeless pancreatic function test in comparison with other indirect and direct tests for exocrine pancreatic function. Digestive diseases and sciences. 1983; 28:490-493.
2. De Baere T, Deschamps F. New tumor ablation techniques for cancer treatment (microwave, electroporation). Diagnostic and interventional imaging. 2014;95(7-8):677-682.
3. Erotokritou A, Gerharz CD, Sagir A. Agenesis of dorsal pancreas associated with pancreatic neuroendocrine tumor: A case report and review of the literature. J Med Case Rep. 2018;12(1):1-7.
4. Li H, Arber S, Jessell TM, Edlund H. Selective agenesis of the dorsal pancreas in mice lacking homeobox gene Hlxb9. Nat Genet. 1999;23(1):67-70.
5. Stanescu DE, Hughes N, Patel P, De Leon DD. A novel mutation in GATA6 causes pancreatic agenesis. Pediatr Diabetes. 2015;16(1): 67-70.
6. Eloubeidi MA, Cohn M, Cerfolio RJ, Chhieng DC, Jhala N, Jhala D, et al. Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis of foregut duplication cysts: The value of demonstrating detached ciliary tufts in cyst fluid. Cancer. 2004;102(4):253-258.
7. Capurso G, Traini M, Piciucchi M, Signoretti M, Arcidiacono PG. Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clinical and experimental Gastroenterology. 2019:129-139.
8. Whipple AO, Parsons WB, Mullins CR. Treatment of carcinoma of the ampulla of vater. Annals of surgery. 1935;102(4):763-779.
9. Boren J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313-2330.
10. Huang HL, Hsing HW, Lai TC, Chen YW, Lee TR, Chan HT, et al. Trypsin-induced proteome alteration during cell subculture in mammalian cells. J Biomed Sci. 2010;17(1):1-10.